US Stock MarketDetailed Quotes

PRRUF IMMUTEP LTD

Watchlist
  • 0.250
  • 0.0000.00%
15min DelayClose Jun 14 09:30 ET
300.44MMarket Cap-9631P/E (TTM)

About IMMUTEP LTD Company

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987, and is headquartered in Sydney, Australia.

Company Profile

SymbolPRRUF
Company NameIMMUTEP LTD
Listing DateApr 16, 2012
Founded1987
CEOMr. Marc Voigt
MarketPink Market
Employees24
Securities TypeOrdinary Shares
Fiscal Year Ends06-30
AddressAustralia Square,264 George Street,Level 32, Suite 32.07
CitySydney
ProvinceNew South Wales (NSW)
CountryAustralia
Zip Code2000
Phone61-2-8315-7003
Websitehttp://www.immutep.com

Company Executives

  • Name
  • Position
  • Salary
  • Marc Voigt
  • Director, Chief Executive Officer, Chief Financial Officer and Managing Director
  • 1.11M
  • Dr. Frederic Triebel, M.D.,PhD
  • Director and Chief Scientific Officer
  • 744.24K
  • Deanne Miller
  • Chief Operating Officer, General Counsel and Company Secretary
  • 595.80K
  • Pete A. Meyers
  • Deputy Chairman of the Board
  • 192.28K
  • Dr. Russell J. Howard, PhD
  • Non-Executive Chairman of the Board
  • 171.99K
  • Lis Boyce
  • Independent Director
  • 62.32K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg